Michelle Moringlane, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Hc 2 Box 13066, Gurabo, PR 00778 Phone: 787-743-4289 Fax: 787-743-4289 |
Dr. Ketsy Pagan Mercado, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Carr 941, Salida Barrio Jaguas, Gurabo, PR 00778 Phone: 787-737-4866 Fax: 787-737-0244 |
Dr. Iliana Alicea, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Hc 3 Box 8911, Gurabo, PR 00778 Phone: 787-412-6782 |
Minela Colon, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Villas Del Golf 85, Ciudad Jardin, Gurabo, PR 00778 Phone: 787-366-5158 |
Rafael Rivera, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: Gran Vista Ii, Plaza Iv # 37, Gurabo, PR 00778 Phone: 787-286-8193 Fax: 787-286-0280 |
Amarilis Padilla Lugo, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Carr 941 Saleda Barrio Jaguas, Gurabo, PR 00778 Phone: 787-737-5033 Fax: 787-737-0244 |
Ana H Vazquez Figueroa, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Eugenio Sanchez Lopez, #54, Gurabo, PR 00778 Phone: 787-737-4200 Fax: 787-737-4200 |
News Archive
Cancer Research UK funded scientists have found seven new sites in the human genome that are linked to men's risk of developing prostate cancer. Their findings are published in Nature Genetics today.
Multidrug-resistant TB (MDR-TB) is the disease caused by TB bacilli that are resistant to at least isoniazid and rifampicin – the two most powerful anti-TB drugs. It results from inconsistent or partial treatment of TB, and develops when public health programmes fail to deliver regular and reliable treatment to TB patients.
The spread of cancer cells may be slowed by targeting the protein km23-1, according to researchers at Penn State College of Medicine.
Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.
Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. Preliminary results of a Mayo Clinic - TGen collaborative study shows the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).
› Verified 9 days ago